| Literature DB >> 31342463 |
Hiroshi Okano1, Tatsunori Nakano2, Ryugo Ito3, Ami Tanaka4, Yuji Hoshi4, Keiji Matsubayashi4, Hiroki Asakawa5, Kenji Nose5, Satomi Tsuruga5, Tomomasa Tochio5, Hiroaki Kumazawa5, Yoshiaki Isono5, Hiroki Tanaka5, Shimpei Matsusaki5, Tomohiro Sase5, Tomonori Saito5, Katsumi Mukai5, Akira Nishimura5, Keiki Kawakami3, Shigeo Nagashima6, Masaharu Takahashi6, Hiroaki Okamoto6.
Abstract
A 64-year-old woman was infected with hepatitis E virus (HEV) during chemotherapy for leukemia. By retrospective analyses of stored serum from the blood products and the patient, the source of the infection was determined to be platelet concentration (PC) transfused during chemotherapy. The partial nucleotide sequence of the HEV strain isolated from the donated PC and that from the patient's sera was identical and was subgenotype 3b. Clinical indicators such as alanine aminotransferase, HEV RNA titer, and anti-HEV antibodies in the serum were investigated from the beginning of the infection until 1 year after the termination of HEV infection. HEV RNA had propagated over 6 months and then cleared spontaneously after the completion of chemotherapy. Anti-HEV antibodies appeared in the serum just before the clearance of HEV RNA. Interestingly, HEV RNA was detected in the patient's urine, spinal fluid, and saliva. The HEV RNA titers in those samples were much lower than in the serum and feces. No renal, neurological, or salivary gland disorders appeared during the follow-up. We observed virological and biochemical progress and cure of transfusion-transmitted chronic hepatitis E in the patient despite an immunosuppressive status during and after chemotherapy against hematological malignancy.Entities:
Keywords: Chemotherapy; Hematological malignancy; Hepatitis E; Immunosuppression; Transfusion
Mesh:
Substances:
Year: 2019 PMID: 31342463 DOI: 10.1007/s12328-019-01024-3
Source DB: PubMed Journal: Clin J Gastroenterol ISSN: 1865-7265